• Something wrong with this record ?

Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding

D. Summer, L. Grossrubatscher, M. Petrik, T. Michalcikova, Z. Novy, C. Rangger, M. Klingler, H. Haas, P. Kaeopookum, E. von Guggenberg, R. Haubner, C. Decristoforo,

. 2017 ; 28 (6) : 1722-1733. [pub] 20170510

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17030844

Positron emission tomography (PET) as well as optical imaging (OI) with peptide receptor targeting probes have proven their value for oncological applications but also show restrictions depending on the clinical field of interest. Therefore, the combination of both methods, particularly in a single molecule, could improve versatility in clinical routine. This proof of principle study aims to show that a chelator, Fusarinine C (FSC), can be utilized as scaffold for novel dimeric dual-modality imaging agents. Two targeting vectors (a minigastrin analogue (MG11) targeting cholecystokinin-2 receptor overexpression (CCK2R) or integrin αVβ3 targeting cyclic pentapeptides (RGD)) and a near-infrared fluorophore (Sulfo-Cyanine7) were conjugated to FSC. The probes were efficiently labeled with gallium-68 and in vitro experiments including determination of logD, stability, protein binding, cell binding, internalization, and biodistribution studies as well as in vivo micro-PET/CT and optical imaging in U-87MG αVβ3- and A431-CCK2R expressing tumor xenografted mice were carried out. Novel bioconjugates showed high receptor affinity and highly specific targeting properties at both receptors. Ex vivo biodistribution and micro-PET/CT imaging studies revealed specific tumor uptake accompanied by slow blood clearance and retention in nontargeted tissues (spleen, liver, and kidneys) leading to visualization of tumors at early (30 to 120 min p.i.). Excellent contrast in corresponding optical imaging studies was achieved especially at delayed time points (24 to 72 h p.i.). Our findings show the proof of principle of chelator scaffolding for hybrid imaging agents and demonstrate FSC being a suitable bifunctional chelator for this approach. Improvements to fine-tune pharmacokinetics are needed to translate this into a clinical setting.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030844
003      
CZ-PrNML
005      
20171030111119.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.bioconjchem.7b00182 $2 doi
035    __
$a (PubMed)28462989
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Summer, Dominik $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
245    10
$a Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding / $c D. Summer, L. Grossrubatscher, M. Petrik, T. Michalcikova, Z. Novy, C. Rangger, M. Klingler, H. Haas, P. Kaeopookum, E. von Guggenberg, R. Haubner, C. Decristoforo,
520    9_
$a Positron emission tomography (PET) as well as optical imaging (OI) with peptide receptor targeting probes have proven their value for oncological applications but also show restrictions depending on the clinical field of interest. Therefore, the combination of both methods, particularly in a single molecule, could improve versatility in clinical routine. This proof of principle study aims to show that a chelator, Fusarinine C (FSC), can be utilized as scaffold for novel dimeric dual-modality imaging agents. Two targeting vectors (a minigastrin analogue (MG11) targeting cholecystokinin-2 receptor overexpression (CCK2R) or integrin αVβ3 targeting cyclic pentapeptides (RGD)) and a near-infrared fluorophore (Sulfo-Cyanine7) were conjugated to FSC. The probes were efficiently labeled with gallium-68 and in vitro experiments including determination of logD, stability, protein binding, cell binding, internalization, and biodistribution studies as well as in vivo micro-PET/CT and optical imaging in U-87MG αVβ3- and A431-CCK2R expressing tumor xenografted mice were carried out. Novel bioconjugates showed high receptor affinity and highly specific targeting properties at both receptors. Ex vivo biodistribution and micro-PET/CT imaging studies revealed specific tumor uptake accompanied by slow blood clearance and retention in nontargeted tissues (spleen, liver, and kidneys) leading to visualization of tumors at early (30 to 120 min p.i.). Excellent contrast in corresponding optical imaging studies was achieved especially at delayed time points (24 to 72 h p.i.). Our findings show the proof of principle of chelator scaffolding for hybrid imaging agents and demonstrate FSC being a suitable bifunctional chelator for this approach. Improvements to fine-tune pharmacokinetics are needed to translate this into a clinical setting.
650    _2
$a zvířata $7 D000818
650    _2
$a chelátory $x chemie $x farmakokinetika $7 D002614
650    _2
$a železité sloučeniny $x farmakokinetika $7 D005290
650    _2
$a radioizotopy galia $x farmakokinetika $7 D005710
650    _2
$a heterografty $7 D064593
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x farmakokinetika $7 D006877
650    _2
$a integrin alfaVbeta3 $x metabolismus $7 D039302
650    _2
$a myši $7 D051379
650    _2
$a molekulární sondy $x chemie $x farmakokinetika $7 D015335
650    _2
$a multimodální zobrazování $x metody $7 D064847
650    _2
$a nádory $x diagnostické zobrazování $x metabolismus $7 D009369
650    _2
$a PET/CT $7 D000072078
650    _2
$a receptor cholecystokininu B $x metabolismus $7 D043887
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
700    1_
$a Grossrubatscher, Leo $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
700    1_
$a Petrik, Milos $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc , Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Michalcikova, Tereza $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc , Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Novy, Zbynek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc , Hnevotinska 5, 779 00, Olomouc, Czech Republic.
700    1_
$a Rangger, Christine $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
700    1_
$a Klingler, Maximilian $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
700    1_
$a Haas, Hubertus $u Division of Molecular Biology/Biocenter, Medical University Innsbruck , Innrain 80-82, A-6020 Innsbruck, Austria.
700    1_
$a Kaeopookum, Piriya $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria. Ministry of Science, Technology (MOST), Thailand Institute of Nuclear Technology (TINT) , Nakhonnayok 26120, Thailand.
700    1_
$a von Guggenberg, Elisabeth $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
700    1_
$a Haubner, Roland $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
700    1_
$a Decristoforo, Clemens $u Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria.
773    0_
$w MED00006454 $t Bioconjugate chemistry $x 1520-4812 $g Roč. 28, č. 6 (2017), s. 1722-1733
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28462989 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171030111208 $b ABA008
999    __
$a ok $b bmc $g 1254437 $s 991871
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 28 $c 6 $d 1722-1733 $e 20170510 $i 1520-4812 $m Bioconjugate chemistry $n Bioconjug Chem $x MED00006454
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options